CSL Ltd
ASX:CSL

Watchlist Manager
CSL Ltd Logo
CSL Ltd
ASX:CSL
Watchlist
Price: 168.29 AUD -2.42% Market Closed
Market Cap: 81.6B AUD

CSL's latest stock split occurred on Oct 18, 2007

The company executed a 3-for-1 stock split, meaning that for every share held, investors received 3 new shares.

The adjusted shares began trading on Oct 18, 2007. This was the only stock split in CSL's history.

Last Splits:
Oct 18, 2007
3-for-1
Pre-Split Price
N/A
Post-Split Price
31.8958
Before
After
Last Splits:
Oct 18, 2007
3-for-1

CSL Ltd
Stock Splits History

CSL Stock Splits Timeline
Oct 18, 2007
Oct 18, 2007
Split 3-for-1
x3
Pre-Split Price
N/A
Post-Split Price
31.8958
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Jan 20, 2026
Linius Technologies Ltd
OTC:LNNTF
1-for-100
/100
0.0001 0.0001 USD N/A
Jan 20, 2026
Lotus Resources Ltd
OTC:LTSRF
1-for-11
/11
0.14 0.14 USD N/A
Jan 15, 2026
Amcor PLC
NYSE:AMCR
1-for-5
/5
8.46 8.46 USD N/A
Jan 8, 2026
Sumitomo Realty & Development Co Ltd
OTC:SURYY
2-for-1
x2
25.635 25.635 USD N/A
Dec 30, 2025
Adicet Bio Inc
NASDAQ:ACET
1-for-16
/16
0.4921 0.4921 USD 7.93 7.93 USD
Load More

CSL Ltd
Glance View

In the bustling world of biotech innovation, CSL Limited stands as a stalwart, renowned for not just navigating but shaping the industry's intricate landscape. Founded in 1916, this Australian giant has grown from its humble beginnings to become a global leader in the biopharmaceutical sector. CSL operates primarily through two main segments: CSL Behring and Seqirus. CSL Behring is the cornerstone of the company's growth, specializing in the development of life-saving therapies derived from human plasma. These therapies are pivotal in treating rare and serious diseases such as hemophilia, immune deficiencies, and hereditary angioedema. The company has built an impressive collection of facilities across several continents, focusing on plasma collection and processing, which underscores its commitment to advanced therapeutic solutions. Alongside CSL Behring, Seqirus has emerged as a formidable force in the influenza vaccine market and is now one of the world's largest flu vaccine providers. The acquisition and transformation of this division signify CSL’s strategic expansion into broader preventive healthcare. From developing and distributing advanced technologies in cell-based and adjuvanted influenza vaccines to advancing research in universal flu vaccines, Seqirus exemplifies CSL's innovative spirit. Collectively, these divisions illustrate how CSL marries cutting-edge research with robust global operations to generate robust revenues, addressing pressing healthcare needs across the globe while promising new horizons in medical science.

CSL Intrinsic Value
219.73 AUD
Undervaluation 23%
Intrinsic Value
Price
Back to Top